Search company, investor...
CSA Medical company logo

CSA Medical

Founded Year



Loan | Alive

Total Raised


Last Raised

$1.5M | 3 yrs ago

About CSA Medical

CSA Medical is a developer of cryospray therapy platforms, truFreeze, and Rejuvenair.

Headquarters Location

91 Hartwell Avenue

Lexington, Massachusetts, 02421,

United States


Missing: CSA Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CSA Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CSA Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CSA Medical is included in 3 Expert Collections, including Medical Devices.


Medical Devices

11,650 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

CSA Medical Patents

CSA Medical has filed 1 patent.

The 3 most popular patent topics include:

  • Medical equipment
  • Cryogenics
  • Surgical procedures and techniques
patents chart

Application Date

Grant Date


Related Topics




Inflammations, Rare diseases, Respiratory therapy, Syndromes, Muscarinic antagonists


Application Date


Grant Date



Related Topics

Inflammations, Rare diseases, Respiratory therapy, Syndromes, Muscarinic antagonists



Latest CSA Medical News

Spiration valve system for emphysema yields sustained quality of life benefit at 2 years

Sep 20, 2022

Source: Criner GJ, et al. Disclosures: Criner reports receiving grants from AstraZeneca, Boehringer Ingelheim, Broncus, Chiesi, Corvus, Genentech, Gilead, GlaxoSmithKline, Fisher-Paykel Healthcare, Lilly, NIH-NHLBI, Novartis, Olympus, PA-DOH, Pfizer, Pearl, PneumRx, Pulmonx, Regeneron, Roche and Spiration; consultant fees from Almirall, AstraZeneca, Broncus, BTG, CSA Medical, GlaxoSmithKline, EOLO, Intuitive, Ion, Mereo, Nuvaira, PneumRx, Pulmonx, Regeneron and Sanofi; and equity interest from Free Flow Medical and Pleural Dynamics. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact . Back to Healio Patients with severe heterogeneous emphysema treated with a support expiration valve system had a sustained clinically significant benefit in health-related quality of life at 24 months in the EMPROVE trial. “Our current treatments for patients with COPD are effective for patients with predominant airways disease to alleviate the hyperinflation that patients face. However, for those with a predominant emphysematous phenotype, it’s challenging for those drugs to give effective relief,” Gerard J. Criner, MD, FACP, FACCP, chair and professor of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University and director of the Temple Lung Center, Philadelphia, said during a presentation at the European Respiratory Society International Congress. Source: Adobe Stock. The prospective, multicenter, randomized controlled EMPROVE trial included 174 patients from 31 sites in North America with advanced emphysema who were older than 40 years with an FEV1 less than 45%, a total lung capacity of 100% or more and a residual volume of 150% or more. Patients were randomly assigned to treatment with the Spiration Valve System (Olympus; n = 113) or the control group (n = 59). For the current analysis, researchers assessed health-related quality of life at 24-month follow-up. Health-related quality of life was determined using the St. George’s Respiratory Questionnaire, the modified Medical Research Council dyspnea scale and the COPD Assessment Test. At 24 months, researchers had data on 80 patients in the treatment group and 34 in the control group. At 24 months, results showed sustained health-related quality of life in patients in the treatment group, Criner said. Mean change from baseline to 24 months in the modified Medical Research Council dyspnea scale was –0.6 points compared with the control group (P < .01). The researchers reported a similar improvement of –6.5 points in the St. George’s Respiratory Questionnaire and –2.6 points on the COPD Assessment Test (P < .05 for both). Change in the global assessment of quality of life was not significant at 24 months. When evaluating FEV1, researchers reported a 90 mL difference at 24 months favoring the treatment group compared with an intergroup difference of 100 mL at 12 months. Both declines in FEV1 were similar, suggesting disease progression and not change in the trajectory of change with treatment vs. the control group, according to Criner. Researchers reported no difference in safety outcomes between the two groups for all serious adverse events plus the components of death, COPD exacerbation, pneumonia or pneumothorax at follow-up. “We concluded from this study, at 24 months, following up the improved data and randomized controlled trial that Spiration Valve System treatment provided a sustained clinically significant benefit and disease-specific health-related quality of life in patients with severe heterogeneous emphysema ,” Criner said. “It also produced statistically significant and clinically meaningful outcomes in lung function dyspnea along with a good safety profile, which indicates durability of its treatment benefits.” Read more about

CSA Medical Frequently Asked Questions (FAQ)

  • When was CSA Medical founded?

    CSA Medical was founded in 1993.

  • Where is CSA Medical's headquarters?

    CSA Medical's headquarters is located at 91 Hartwell Avenue, Lexington.

  • What is CSA Medical's latest funding round?

    CSA Medical's latest funding round is Loan.

  • How much did CSA Medical raise?

    CSA Medical raised a total of $156.51M.

  • Who are the investors of CSA Medical?

    Investors of CSA Medical include Paycheck Protection Program, InterSouth Partners, SV Health Investors, First Analysis, Ascension Ventures and 9 more.

  • Who are CSA Medical's competitors?

    Competitors of CSA Medical include CardioFocus, Entellus Medical, TruTouch Technologies, Ornim Medical, ASL Analytical and 12 more.

Compare CSA Medical to Competitors

ViOptix Logo

ViOptix is a medical device company that develops ODISsey Tissue Oximeter.


Tomophase Corporation was founded with the mission of developing solutions for minimally invasive diagnostic (MID) imaging. The company is using light to guide new ways of diagnosing diseases and has conceived major ideas for an optical MID imaging system

OrthAlign Logo

OrthAlign provides orthopedic surgeons with user-friendly and cost-effect technology for precise alignment.

Ornim Medical Logo
Ornim Medical

Ornim specializes in clinical research, development, and distribution of the highest quality medical devices in the field of tissue and cerebral blood flow and perfusion. The Company's leading product, the c-FLOW, is a bedside patient monitor based on the patented UTLight technology that provides physicians with unique monitoring solutions, revolutionizing individualized and personalized patient care.


IntraTherm is focused on continuous improvement of the medical device industry through the introduction of processes and products that aid surgeons and patients in their fight against cancer. The company's product is designed to complement surgery by sterilizing the site of surgery via a controllable and predictable thermal ablation device, with less than minimal short term, and without long term side effects.

Power Medical Interventions

Power Medical Interventions (PMI) is a medical device company headquartered in Langhorne, Pennsylvania. Founded in 2000, PMI was formed for the purpose of designing, developing, and marketing new computerized and reusable devices and methods for delivering staples during surgery. This forms the basis of their SurgASSIST System which is a computer-mediated transection and anastomosis device.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.